ABC²'s Research Showcase: INSIGhT - The First-Ever Adaptive Clinical Trial for Glioblastoma

Share Article

Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute, will be the featured speaker at the October 24th luncheon and webinar.

ABC² Research Showcase - October 24th

"We're focused on developing the most promising and tailored treatments for patients today - and that's the aim of INSIGhT." -Max Wallace, CEO of ABC²

On Tuesday, October 24th, ABC² (Accelerate Brain Cancer Cure) will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, but registration is required.

WHAT: ABC² Brain Cancer Research Lunch & Learn

WHEN: October 24, 2017, 11:30 AM – 1:30 PM

WHERE: The Case Foundation, 1717 Rhode Island Ave. NW, Suite 700, Washington, DC 20036

11:30 am – 11:50 am – “Next Generation Clinical Trials and Personalized Medicine”

Speaker: Max Wallace, CEO, ABC²

11:50 am - 12:30 pm – Lunch

12:30 pm – 1:30 pm – “INSIGhT Adaptive Clinical Trial for GBM” (For those unable to attend in person, a live webcast of the discussion is scheduled to begin at 12:30 pm EST on Facebook Live)

Speakers: Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute and David Sandak, Senior Vice President, Strategy and Research, ABC²
Moderator: Max Wallace, CEO, ABC²

INSIGhT is the first-ever adaptive clinical trial in brain cancer. It matches targeted therapies with the patients most likely to benefit from them.

Dana Farber is leading a 10-institution consortium (Massachusetts General Hospital, The University of Alabama at Birmingham, Mayo Clinic, Columbia, Cleveland Clinic, MD Anderson, University of Pittsburgh, Utah/Huntsman, and University of Virginia) that will test multiple drugs in newly diagnosed patients in a rapidly adaptive environment. Five institutions in the consortium have now begun recruiting patients and the others are soon to follow.

As part of this, ABC² has joined with three pharmaceutical companies (Eli Lilly, Celgene and Puma Biotechnology) to fund the trial and ABC²'s Allele system does the front-end molecular analysis placing patients into the treatment arm most suitable for their individual tumor.

"In the past, glioblastoma patients have faced limited treatment options and a grim prognosis," says Max Wallace, CEO of ABC². "We're focused on developing the most promising and tailored treatments for patients today - and that's the aim of INSIGhT."

To RSVP for the lunch discussion, please click HERE or email info(at)abc2(dot)org by October 13th.

2017 Science Salon Series Sponsored by Genentech

About ABC² (Accelerate Brain Cancer Cure)
ABC² is focused on speeding the discovery of a cure for brain cancer. By applying an aggressive, venture funding approach not typically seen in the nonprofit sector, ABC² closes current gaps in funding in order to catalyze research and rapidly bring new therapies to patients. ABC² has awarded more than 100 grants totaling $20 million in brain tumor research funding to highly qualified investigators and physician-scientists from 54 institutions and companies. Since its founding in 2001, ABC² has helped bring 30 different treatments into the clinic. To learn more, visit http://www.abc2.org.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicola Beddow
@BrainCancerCure
Follow >
Visit website